Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind study of Relutrigine in pediatric SCN2A-DEE and SCN8A-DEE with open-label extension
MOH_2025-07-08_014119Phase 2Not yet recruiting
- Sponsor
- Praxis Precision Medicines
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of relutrigine in SCN2A developmental and epileptic encephalopathy (SCN2A-DEE) and developmental and epileptic encephalopathy 13 (DEE13) (3 arms), sponsored by Praxis Precision Medicines. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
relutrigine
03
Conditions
SCN2A developmental and epileptic encephalopathy (SCN2A-DEE)developmental and epileptic encephalopathy 13 (DEE13)
Beyond the preview
Go deeper on MOH_2025-07-08_014119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-07-08_014119.